Recovery of coronary flow and left ventricular function after abciximab.
Mak
K H
KH
Department of Cardiology National Heart Centre, Tan Hospital, Singapore.
Neumann
F J
FJ
Blasini
M R
MR
Schmitt
M C
MC
Alt
M E
ME
Dirschinger
M J
MJ
Gawaz
M M
MM
Kastrati
M A
MA
Schömig
M A
MA
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D003326:Coronary Circulation / Q000187:drug effects; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D015607:Stents; D016277:Ventricular Function, Left / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D006493:Heparin; D000077284:Abciximab